Format

Send to

Choose Destination
J Hum Virol. 1998 May-Jun;1(4):293-8.

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

Author information

1
Hemophilia and Thrombosis Center Angelo Bianchi Bonomi, IRCCS Maggiore Hospital, Milan, Italy. hemophilia_ctr@polic.cilea.it

Abstract

OBJECTIVES:

To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients.

METHOD:

The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3).

RESULTS:

Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro.

CONCLUSION:

These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

PMID:
10195254
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center